Oxybutynin and Omega-3 for OAB (Overactive Bladder)

Recruiting in Palo Alto (17 mi)

Age: 18+

Sex: Female

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Waitlist Available

Sponsor: TriHealth Inc.

Trial Summary

What is the purpose of this trial?

We aim to evaluate whether the addition of Omega-3 fatty acids to oxybutynin, a standard first-line treatment for overactive bladder syndrome, will improve symptoms and quality of life. Secondarily, we will evaluate whether Omega-3 fatty acids help reduce the adverse effects of oxybutynin. Hypothesis * Primary: Omega-3 will enhance the beneficial role of oxybutynin in the treatment of overactive bladder (OAB) * Secondary: Omega-3 will reduce the side effects of dry eyes and constipation associated with oxybutynin

Research Team

Rachel Pauls, MD

Principal Investigator

TriHealth Inc.

Eligibility Criteria

Inclusion Criteria

Women between the ages of 18-85; Desiring treatment for symptoms of urinary frequency, defined as >8 voids/day and/or nocturia > 1 void/night or urge incontinence episodes of >1/day

Treatment Details

Interventions

Omega 3 Fatty Acid (Other)
Placebo (Other)

Participant Groups

2Treatment groups

Experimental Treatment

Placebo Group

Group I: Omega- 3 Fatty AcidExperimental Treatment1 Intervention

The patient will receive oxybutynin 5 mg twice daily (BID). The patients in the study group will receive a 0.9 gm capsule of Omega-3 BID. The amount of medication was chosen based on dosage used in prior studies and the current FDA recommendations to not exceed 2gm/day of omega-3 in dietary supplementation.

Group II: PlaceboPlacebo Group1 Intervention

Seagate® Extra Virgin Olive oil capsules